RecruitingPHASE1, PHASE2NCT05636618
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Studying Bronchial neuroendocrine tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Perspective Therapeutics
- Intervention
- [203Pb]VMT-α-NET(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 18-90 years · All sexes
- Timeline
- 2023 – 2029
Study locations (17)
- Mayo Clinic, Jacksonville, Florida, United States
- Biogenix Molecular, Miami, Florida, United States
- The University of Chicago, Chicago, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- University of Kentucky, Lexington, Kentucky, United States
- Johns Hopkins, Baltimore, Maryland, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- BAMF Health, Grand Rapids, Michigan, United States
- Michigan Health Professionals, Troy, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University, St Louis, Missouri, United States
- Nebraska Cancer Specialists, Omaha, Nebraska, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- Ohio State University, Columbus, Ohio, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05636618 on ClinicalTrials.govOther trials for Bronchial neuroendocrine tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07174583A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerIDEAYA Biosciences
- RECRUITINGNANCT07555210Pilot Study of Bone Mineral Density Changes During Anti-PD-1 ImmunotherapyJessica Mezzanotte Sharpe
- RECRUITINGPHASE2NCT04665739Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT05522660Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung CancerETOP IBCSG Partners Foundation
- RECRUITINGPHASE1NCT04429087A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Boehringer Ingelheim
- ACTIVE NOT RECRUITINGPHASE1NCT02589522Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine TumorsNational Cancer Institute (NCI)
- ENROLLING BY INVITATIONNCT00068003Harvesting Cells for Experimental Cancer TreatmentsNational Cancer Institute (NCI)